Entity

Time filter

Source Type

Turku, Finland

Patent
Wallac Oy | Date: 2012-04-02

A measurement device includes mechanical support elements (


A method for predicting risk of gestational diabetes mellitus (GDM) in a pregnant individual includes measuring one or more biochemical markers in a blood sample obtained from the pregnant individual to determine one or more biomarker levels, where the one or more measured biochemical markers includes at least one of PAI-2 and sTNFR1, identifying, for each of the one or more measured biochemical markers, a difference between the measured biomarker level and a corresponding predetermined control level, and, responsive to the identifying, determining a prediction corresponding to a relative risk of the pregnant individual having or developing GDM.


A method for predicting risk of pre-eclampsia in a pregnant individual includes measuring one or more biochemical markers including an RBP4 biochemical marker in a blood sample obtained from the pregnant individual to determine one or more biomarker levels including an RBP4 biomarker level, identifying, for each of the one or more measured biochemical markers, a difference between the measured biomarker level and a corresponding predetermined control level, and, responsive to the identifying, determining a prediction corresponding to a relative risk of the pregnant individual having or developing pre-eclampsia.


A method for cross-talk correction of intensities measured on mutually separate detection wavelength bands is presented. Each detection wavelength band relates to one of analyte-specific probe-populations contained by a sample to be analyzed. Each probe-population is capable of emitting a first signal component and a second signal component whose spectra have maxima at different wavelengths and at least the first signal component is dependent on presence of analyte detectable with that probe-population. Cross-talk corrected intensities are computed on the basis of a) the intensities measured on the detection wavelength bands, b) a value indicative of intensity occurring on an auxiliary wavelength band outside the detection wavelength bands and at least partially caused by the second signal components, and c) pre-determined cross-talk parameters. For example in con-junction with FRET-based assays, the dependency of a background signal on the percentage of hybridized probes can be taken into account in the cross-talk correction.


Patent
Perkin Elmer Corporation, Foundation Medicine and Wallac Oy | Date: 2013-12-31

The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers.

Discover hidden collaborations